Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7318)
All Articles published online
|
Publishing Process of This Article
|
Jun 24, 2013 (publication date) through May 4, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Transplantation
ISSN
2220-3230
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Salvadori M, Bertoni E. Is it time to give up with calcineurin inhibitors in kidney transplantation? World J Transplant 2013; 3(2): 7-25 [PMID: 24175203 DOI: 10.5500/wjt.v3.i2.7] |
|---|---|
| URL: | https://www.wjgnet.com/2220-3230/full/v3/i2/7.htm |
| Number | Citing Articles |
| 1 |
Fuad Shihab, Uwe Christians, Lonnie Smith, Jason R. Wellen, Bruce Kaplan. Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure–response relationships, and clinical outcomes. Transplant Immunology 2014; 31(1): 22 doi: 10.1016/j.trim.2014.05.002
|
| 2 |
B. Tönshoff. Minimierung der immunsuppressiven Therapie mit Calcineurininhibitoren nach Nierentransplantation?. Der Nephrologe 2015; 10(5): 419 doi: 10.1007/s11560-015-1001-6
|
| 3 |
Hina Khalid, Muhammad Mazhar Fareed, Thomas Dandekar, Sergey Shityakov. Calcineurin and mTOR inhibitors in kidney transplantation: integrative metamodeling on transplant survival and kidney function. International Urology and Nephrology 2023; 56(4): 1403 doi: 10.1007/s11255-023-03754-3
|
| 4 |
James Reuberson, Helen Horsley, Richard J. Franklin, Daniel Ford, Judi Neuss, Daniel Brookings, Qiuya Huang, Bart Vanderhoydonck, Ling-Jie Gao, Mi-Yeon Jang, Piet Herdewijn, Anant Ghawalkar, Farnaz Fallah-Arani, Adnan R. Khan, Jamie Henshall, Mark Jairaj, Sarah Malcolm, Eleanor Ward, Lindsay Shuttleworth, Yuan Lin, Shengqiao Li, Thierry Louat, Mark Waer, Jean Herman, Andrew Payne, Tom Ceska, Carl Doyle, Will Pitt, Mark Calmiano, Martin Augustin, Stefan Steinbacher, Alfred Lammens, Rodger Allen. Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in Vivo. Journal of Medicinal Chemistry 2018; 61(15): 6705 doi: 10.1021/acs.jmedchem.8b00521
|
| 5 |
Robert C. Harland, Goran Klintmalm, Stephen Jensik, Harold Yang, Jonathan Bromberg, John Holman, Mysore S.A. Kumar, Vicki Santos, Tami J. Larson, Xuegong Wang. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. American Journal of Transplantation 2020; 20(1): 159 doi: 10.1111/ajt.15591
|
| 6 |
Eleanor M Bolton, John Andrew Bradley. Avoiding immunological rejection in regenerative medicine. Regenerative Medicine 2015; 10(3): 287 doi: 10.2217/rme.15.11
|
| 7 |
G. Laham, R. Scuteri, P. Cornicelli, M. Arriola, P.M. Raffaele, M. Davalos Michel, N. Imperiali, R.M. Fortunato, E.C. Maggiora, M.V. Sal, G. Soler Pujol. Surveillance Registry of Sirolimus Use in Recipients of Kidney Allografts From Expanded Criteria Donors. Transplantation Proceedings 2016; 48(8): 2650 doi: 10.1016/j.transproceed.2016.08.008
|
| 8 |
Opas Traitanon, James M Mathew, Giovanna La Monica, Luting Xu, Valeria Mas, Lorenzo Gallon, Derya Unutmaz. Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells. PLOS ONE 2015; 10(6): e0129658 doi: 10.1371/journal.pone.0129658
|
| 9 |
Goce Spasovski, Lada Trajceska, Irena Rambabova-Bushljetik. Pharmacotherapeutic options for the prevention of kidney transplant rejection: the evidence to date. Expert Opinion on Pharmacotherapy 2022; 23(12): 1397 doi: 10.1080/14656566.2022.2102418
|
| 10 |
Faouzi Saliba, Christophe Duvoux, Sébastien Dharancy, Jérôme Dumortier, Yvon Calmus, Jean Gugenheim, Nassim Kamar, Ephrem Salamé, Martine Neau‐Cransac, Claire Vanlemmens, François Durand, Georges‐Philippe Pageaux, Jean Hardwigsen, Yasmina Benkhatar, François Derquenne, Filomena Conti. Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study. Liver International 2022; 42(11): 2513 doi: 10.1111/liv.15396
|
| 11 |
Arthur J. Matas, Robert S. Gaston. Moving Beyond Minimization Trials in Kidney Transplantation. Journal of the American Society of Nephrology 2015; 26(12): 2898 doi: 10.1681/ASN.2015030245
|
| 12 |
James M. Neuberger, Wolf O. Bechstein, Dirk R.J. Kuypers, Patrizia Burra, Franco Citterio, Sabina De Geest, Christophe Duvoux, Alan G. Jardine, Nassim Kamar, Bernhard K. Krämer, Herold J. Metselaar, Frederik Nevens, Jacques Pirenne, Manuel L. Rodríguez-Perálvarez, Didier Samuel, Stefan Schneeberger, Daniel Serón, Pavel Trunečka, Giuseppe Tisone, Teun van Gelder. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients. Transplantation 2017; 101(4S): S1 doi: 10.1097/TP.0000000000001651
|
| 13 |
Agnieszka Urzykowska, Barbara Piątosa, Urszula Grycuk, Grzegorz Kowalewski, Zbigniew Kułaga, Ryszard Grenda. Evaluation of Cumulative Effect of Standard Triple Immunosuppression on Prevention of De Novo Donor Specific Antibodies (dnDSA) Production in Children after Kidney Transplantation—A Retrospective and Prospective Study. Children 2021; 8(12): 1162 doi: 10.3390/children8121162
|
| 14 |
Fei Liu, Jian-Hua Mao. Calcineurin inhibitors and nephrotoxicity in children. World Journal of Pediatrics 2018; 14(2): 121 doi: 10.1007/s12519-018-0125-y
|
| 15 |
Maria del Carmen Rial, Helio Tedesco Silva, Alvaro Pacheco-Silva, José Cruz, Rodolfo Torres, Bartholomew J. Tortella, Huihua Li, Pablo Cornicelli, Carlos Estevez. Adverse Events and Discontinuation Rates Associated with Sirolimus Treatment in Adult Renal Transplant Patients in Latin America vs Non–Latin American Countries. Transplantation Proceedings 2020; 52(3): 767 doi: 10.1016/j.transproceed.2020.01.040
|
| 16 |
Alberto Baroja-Mazo, Beatriz Revilla-Nuin, Pablo Ramírez, José A Pons. Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation. World Journal of Transplantation 2016; 6(1): 183-192 doi: 10.5500/wjt.v6.i1.183
|
| 17 |
Song C. Ong, Robert S. Gaston. Thirty Years of Tacrolimus in Clinical Practice. Transplantation 2021; 105(3): 484 doi: 10.1097/TP.0000000000003350
|
| 18 |
Mark D. Stegall, Robert S. Gaston, Fernando G. Cosio, Arthur Matas. Through a Glass Darkly. Journal of the American Society of Nephrology 2015; 26(1): 20 doi: 10.1681/ASN.2014040378
|
| 19 |
Marja van Dijk, Arie M. van Roon, M. Yusof Said, Frederike J. Bemelman, Jaap J. Homan van der Heide, Hans W. de Fijter, Aiko P. J. de Vries, Stephan J. L. Bakker, Jan Stephan F. Sanders. Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial. Transplant International 2018; 31(12): 1380 doi: 10.1111/tri.13322
|
| 20 |
Yoko Kurata, Takafumi Kuzuya, Yuko Miwa, Kenta Iwasaki, Masataka Haneda, Katsuo Amioka, Kiyofumi Yamada, Yoshihiko Watarai, Akio Katayama, Kazuharu Uchida, Takaaki Kobayashi. Clinical relevance of post-transplant pharmacodynamic analysis of cyclosporine in renal transplantation. International Immunopharmacology 2014; 22(2): 384 doi: 10.1016/j.intimp.2014.07.022
|
| 21 |
Takenori Niioka, Hideaki Kagaya, Mitsuru Saito, Takamitsu Inoue, Kazuyuki Numakura, Ryohei Yamamoto, Yumiko Akamine, Tomonori Habuchi, Shigeru Satoh, Masatomo Miura. Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients. International Journal of Urology 2016; 23(6): 484 doi: 10.1111/iju.13081
|
| 22 |
Jayant Kumar, Isabella Reccia, Francesco Virdis, Mauro Podda, Ajay Kumar Sharma, Ahmed Halawa. Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review. World Journal of Transplantation 2021; 11(3): 70-86 doi: 10.5500/wjt.v11.i3.70
|
| 23 |
V. Turunç, S.B. Açıkgöz, H. Dheir. Early Switch to Mammalian Target of Rapamycin Inhibitors Is a Sustainable Treatment Approach in Renal Transplant Recipients: 7-Year Results. Transplantation Proceedings 2019; 51(4): 1070 doi: 10.1016/j.transproceed.2019.01.098
|
| 24 |
Cyd M. Castro-Rojas, Rita R. Alloway, E. Steve Woodle, David A. Hildeman. High-Dimensional Renal Profiling: Towards a Better Understanding of Renal Transplant Immune Suppression. Current Transplantation Reports 2019; 6(1): 60 doi: 10.1007/s40472-019-0225-1
|
| 25 |
Fernando Gonzalez. Empirical or unconscious reduction of the secondary immunosuppressive drug concomitantly with intended calcineurin inhibitor reduced exposure to improve kidney graft function can be followed by antibody mediated rejections. Clinical Transplantation 2015; 29(4): 277 doi: 10.1111/ctr.12512
|
| 26 |
Mohammad Hossein Karimi, Saeed Marzban, Mohammad Reza Hajiyan, Bita Geramizadeh, Ali Akbar Pourfathollah, Mohammad Hassan Rajabiyan, Salimeh Ebrahimnezhad. Effect of CD40 silenced dendritic cells by RNA interference on mice skin allograft rejection. Immunotherapy 2015; 7(2): 111 doi: 10.2217/imt.14.112
|
| 27 |
L. Song, A. Ma, H. Dun, Y. Hu, Y. Fujii, F. Kinugasa, S. Oshima, Y. Higashi, P. Daloze, H. Chen. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys. American Journal of Transplantation 2017; 17(3): 635 doi: 10.1111/ajt.14039
|
| 28 |
|